Surrogate endpoints shortening the therapeutic evaluation duration for different subgroups of patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: A retrospective analysis of 830 patients stratified by the 8th edition of the UICC/AJCC staging system and plasma Epstein-Barr viral

Conclusions: The time of therapeutic evaluation could be shortened to <5-year in stages I-II patients. The year of surrogate endpoints could be ahead in stages II-IVA with high EBV DNA.

Source: Journal of Cancer - December 14, 2018 Category: Cancer & Oncology Authors: Shu Zhou, Chen Chen, Song-ran Liu, Ya-lan Tao, Hui Chang, Xiao-hui Wang, Xin Yang, Wen-wen Zhang, Shan Liu, Shi-rong Ding, Guan-nan Wang, Yun-fei Xia Tags: Research Paper Source Type: research